Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
Date:2/8/2010

fectively reduce symptoms such as fever, shakes, cough, shortness of breath, and sore throat. According to Tianyin's market research and estimation, annual sales of this type of products are approximately $1.1 billion in China. The Antibacterial/Anti-inflammatory Capsules are a generic OTC TCM used as natural antibiotics to treat bacterial infection and inflammation with minimal side effects as compared to western antibiotics. Tianyin estimates that total annual sales of associated with products in this category are approximately $1.5 billion in China. -- Tianyin announced that 23 of its medicine compounds were included in the 2009 Edition of the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Medicine Directory, which lists a total of 2,151 medicines and became effective on December 1, 2009. The 23 medicines treat a variety of common indications and diseases and make up approximately 70% of Tianyin's total revenues for the fiscal year 2009. -- On January 11, 2010, Tianyin declared a quarterly cash dividend of 2.5 cents to be paid to its common stock shareholders for the fiscal second quarter of 2010 on March 10, 2010. -- On January 13, 2010, Tianyin received approvals from the Chinese State Food and Drug Administration (SFDA) to produce two generic antibiotics, Ofloxacin Tablets and Fleroxacin Tablets, which target new indications for the Company. Ofloxacin addresses several indications including staph, strep throat (Streptococcus), pneumonia, E. Coli, and several sexually transmitted bacterial diseases. Fleroxacin addresses several indications including chronic and acute bronchitis and pneumonia, salmonella, multiple gastrointestinal and abdominal infections, and skin/soft tissue infections. Both drugs are included in China's Essential Drug Li
'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
2. Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET
3. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
4. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
5. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
6. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
7. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
8. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
9. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
10. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
11. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 Sales Horizons, a leader in ... online sales skills training course to help companies ... clinical staff spend the majority of their time on ... center, or physician practice – providing support and education ... there? Sales Horizons believes clinical staff are and should ...
(Date:8/18/2014)... (Aug. 18, 2014) -- A new therapy developed ... (USF) Morsani College of Medicine and Columbia University ... complications of interventional cardiovascular disease treatment. , ... the novel molecular therapy could selectively inhibit blood ... a medical procedure using a balloon catheter to ...
(Date:8/18/2014)... Md. , Aug. 18, 2014 /PRNewswire/ ... maker of advanced consumer medical devices said ... was interviewed by CEOLIVE.TV as part ... The entire interview is available at ... Dr. Kotak explains to investors the unique ...
(Date:8/18/2014)... NYElectronic devices with unprecedented efficiency and data ... that use built-in electric polarizations to read ... inside most popular data-driven technology. But ferroelectrics ... blocks, including a curious habit of "forgetting" ... the U.S. Department of Energy,s Brookhaven National ...
Breaking Biology Technology:Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4
... ROCKVILLE, Md., Nov. 4 Novavax, Inc. (Nasdaq:,NVAX) today ... financial,results in a press release to be issued after ... will hold an investor conference call to,discuss its financial ... The call will be hosted by Novavax President and ...
... Lead Cancer Stem Cell Product Candidate Enters Clinical ... OncoMed Pharmaceuticals, a,clinical-stage company developing novel antibody therapeutics ... completion of the final,tranche of its Series B ... total Series B financing to $154 million. New ...
... at Berlin conference, RALEIGH, N.C., Nov. 4 ... it will present during the,Partnerships in Clinical Trials ... PRA,s Christian Tucat, Senior Vice President of Business,Development ... evolution of CRO,partnerships?" at 4PM on Wednesday, 5 ...
Cached Biology Technology:Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call 2OncoMed Pharmaceuticals Completes Series B Financing 2OncoMed Pharmaceuticals Completes Series B Financing 3PRA International Addresses Sponsor-CRO Partnering Strategies at European Partnerships in Clinical Trials Congress 2
(Date:8/20/2014)... bags could one day be made out of cocoa, ... now reporting. The novel process they developed and their ... agricultural and plastic waste problems, appear in the ACS ... Bayer and colleagues at the Italian Institute of Technology ... 2012, its production reached 288 million tons worldwide, but ...
(Date:8/20/2014)... to about 4,000 members, it triggers an important first ... special type of comb used for rearing male reproductive, ... of Neurobiology and Behaviour at Cornell University, led by ... honeybee colonies. The results are published in Springer,s journal ... , Reproduction isn,t always a honeybee colony,s top priority. ...
(Date:8/20/2014)... ROBERTS, Washington , August 20, 2014 ... Security Concerns in the Payment Industry?   ... sectors including biometrics, issues commentary from analysts and experts on ... , Managing Partner at Thrive Analytics, Isabelle Moeller ... of NXT-ID, Inc. (OTCBB: NXTD) ( OTCQB:NXTD ), a biometric ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7
... Vision Australia (BVA) today unveils their wide-view neurostimulator concept ... Australia,s first recipient of the technology. The ... University of New South Wales and unveiled today at ... Melbourne, will deliver improved quality of life for patients ...
... helping fight a multi-front war on cancer may do the ... Cancer and cardiovascular disease, both among top U.S. killers, ... as a treatment could become additional common ground, said Dr. ... think hsp90 inhibitors may be some of the best anti-inflammatory ...
... March 30, 2010 Two new tuberculosis studies by ... bad news about the bacterium that infects nearly a ... kills nearly 2 million people each year. ... shows promise at overcoming some drug-resistant tuberculosis, at least ...
Cached Biology News:Bionic Vision Australia puts bionic eye in sight 2New cancer therapy may fight cardiovascular disease 2UT Southwestern researchers find clues to TB drug resistance 2UT Southwestern researchers find clues to TB drug resistance 3
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
...
Request Info...
... and miRNA Isolation Traditional mRNA isolation ... and can result in the loss of ... miRNA Isolation Kit purifies all RNA species ... Through an enrichment procedure included in the ...
Biology Products: